Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin
Clinical trial NCT05910177 · RECRUITING
Trial details
- NCT number
- NCT05910177
- Sponsor
- Fujian Cancer Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-28
- Primary completion
- 2026-08-31
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.